GLP-1 Receptor Agonist Global Market Opportunities And Strategies To 2035

Description

GLP-1 receptor agonist are a class of medications that mimic the action of the natural hormone glucagon-like peptide-1 (GLP-1), which helps regulate blood sugar levels. These drugs enhance insulin secretion, reduce glucagon production, slow gastric emptying and promote satiety. The primary purpose of GLP-1 receptor agonist is to improve blood glucose control and support weight reduction in patients with type 2 diabetes or obesity.

The GLP-1 receptor agonist market consists of sales, by entities (organizations, sole traders, or partnerships), of products and services related to GLP-1 receptor agonist, that gained approval for use in individuals with obesity, including those without diabetes, to assist in achieving and maintaining weight loss, especially in cases where traditional lifestyle interventions have been ineffective.

The global GLP-1 receptor agonist market was valued at $13,661.7 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 37.00%.

Increased Diagnosis Rates Of Metabolic Disorders

During the historic period, the GLP-1 receptor agonist market was mainly driven by the increased diagnosis rates of metabolic disorders. As screening initiatives expanded and health systems strengthened their capacity to detect conditions such as diabetes earlier, the number of individuals entering clinical management pathways grew substantially. For instance, in 2022, according to a study published in The Lancet Gastroenterology & Hepatology, a peer-reviewed medical journal focused on research and clinical advances in gastroenterology, hepatology and gastrointestinal surgery, the prevalence of non-alcoholic fatty liver disease (NAFLD) was 32%. The overall incidence reached 46.9 cases per 1,000 person-years, rising to 70.8 in men and 29.6 in women. Therefore, the GLP-1 receptor agonist market was mainly driven by the increased diagnosis rates of metabolic disorders.

Development Of Oral GLP-1 Candidates To Expand Patient Convenience And Treatment Accessibility

Major companies in the GLP-1 receptor agonist market are focusing on the development of oral GLP-1 formulations designed to address rising global demand for more convenient, non-injectable metabolic therapies. These innovations aim to improve treatment adherence, reduce reliance on injectable delivery systems and broaden therapeutic accessibility for individuals managing obesity and type 2 diabetes. For instance, in April 2025, Pfizer, a US-based pharmaceutical company specializing in metabolic and cardiometabolic drug development, provided an update on its oral GLP-1 receptor agonist candidate, danuglipron, following the completion of once-daily formulation studies intended to improve dosing convenience for patients. While the candidate achieved pharmacokinetic objectives, the program was discontinued due to a single case of potential liver injury among over 1,400 trial participants. This update underscores both the promise and the complexity of advancing oral GLP-1 drug technology, highlighting ongoing industry efforts to balance innovation, safety and patient-centric design as companies work to meet evolving global treatment needs.

The global GLP-1 receptor agonist market is highly concentrated, with large players operating in the market. The top seven competitors in the market made up 93.89% of the total market in 2024.

GLP-1 Receptor Agonist Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global GLP-1 receptor agonist market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for GLP-1 receptor agonist? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The GLP-1 receptor agonist market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider GLP-1 receptor agonist market; and compares it with other markets.

The report covers the following chapters

Introduction And Market Characteristics Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug class, by route of administration and by end users.
Key Trends Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
Market Segmentation Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by drug class, by route of administration and by end users in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
Regional Market Size And Growth Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking Briefs on the financials comparison between major players in the market.
Competitive Dashboard Briefs on competitive dashboard of major players.
Key Mergers And Acquisitions Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Recent Developments Information on recent developments in the market covered in the report.
Market Opportunities And Strategies Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations This section includes recommendations for GLP-1 receptor agonist providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report

Markets Covered:

1) By Drug Class: Liraglutide; Semaglutide; Tirzepatide; Dulaglutide; Other Drugs
2) By Route Of Administration: Parenteral; Oral
3) By End Users: Hospitals; Surgical Clinics; Other Users
Companies Mentioned: Novo Nordisk AS; Eli Lilly Company; AstraZeneca Inc.; Sanofi SA; Glenmark Pharmaceuticals Limited.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; GLP-1 receptor agonist indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: PH5MG1RA01_G26Q1

1 Executive Summary

1.1 GLP-1 Receptor Agonist - Market Attractiveness And Macro Economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition
6.2 Summary
6.3 GLP-1 Receptor Agonist Market Definition And Segmentations
6.4 Market Segmentation By Drug Class
- 6.4.1 Liraglutide
- 6.4.2 Semaglutide
- 6.4.3 Tirzepatide
- 6.4.4 Dulaglutide
- 6.4.5 Other Drugs
6.5 Market Segmentation By Route Of Administration
- 6.5.1 Parenteral
- 6.5.2 Oral
6.6 Market Segmentation By End Users
- 6.6.1 Hospitals
- 6.6.2 Surgical Clinics
- 6.6.3 Other Users

7 Major Market Trends

7.1 Development Of Oral GLP-1 Candidates To Expand Patient Convenience And Treatment Accessibility
7.2 Integration Of Dual GLP-1/GIP Agonist To Enhance Weight-Loss Efficacy In Obesity Treatment
7.3 Launch Of Dual GLP-1/Glucagon Agonist To Address Metabolic Liver Disease Needs

8 Global GLP-1 Receptor Agonist Growth Analysis And Strategic Analysis Framework

8.1 Global GLP-1 Receptor Agonist Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
- 8.1.1 Political
- 8.1.2 Economic
- 8.1.3 Social
- 8.1.4 Technological
- 8.1.5 Environmental
- 8.1.6 Legal
8.2 Analysis Of End User (B2B And B2C)
- 8.2.1 Hospital
- 8.2.2 Surgical Clinics
- 8.2.3 Other Users
8.3 Global GLP-1 Receptor Agonist Market Growth Rate Analysis
8.4 Historic Market Growth, 2020 - 2025, Value ($ Million)
- 8.4.1 Market Drivers 2020 - 2025
- 8.4.2 Market Restraints 2020 - 2025
8.5 Forecast Market Growth, 2025 - 2030, 2035F Value ($ Million)
8.6 Forecast Growth Contributors/Factors
- 8.6.1 Quantitative Growth Contributors
- 8.6.2 Drivers
- 8.6.3 Restraints
8.7 Global GLP-1 Receptor Agonist Total Addressable Market (TAM)
- 8.7.1 TAM Comparison Analysis

9 Global GLP-1 Receptor Agonist Market Segmentation

9.1 Global GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
9.2 Global GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
9.3 Global GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
9.4 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Liraglutide, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
9.5 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Semaglutide, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
9.6 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Tirzepatide, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
9.7 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Dulaglutide, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
9.8 Global GLP-1 Receptor Agonist Market, Sub-Segmentation Of Other Drugs, By Type, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

10 GLP-1 Receptor Agonist Market, Regional and Country Analysis

10.1 Global GLP-1 Receptor Agonist Market, By Region, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
10.2 Global GLP-1 Receptor Agonist Market, By Country, Historic and Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

11 Asia-Pacific Market

11.1 Summary
11.2 Market Overview
- 11.2.1 Region Information
- 11.2.2 Market Information
- 11.2.3 Background Information
- 11.2.4 Government Initiatives
- 11.2.5 Regulations
- 11.2.6 Regulatory Bodies
- 11.2.7 Major Associations
- 11.2.8 Taxes Levied
- 11.2.9 Corporate Tax Structure
- 11.2.10 Investments
- 11.2.11 Major Companies
11.3 Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.4 Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.5 Asia-Pacific GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.6 China Market
11.7 Summary
11.8 Market Overview
- 11.8.1 Country Information
- 11.8.2 Market Information
- 11.8.3 Background Information
- 11.8.4 Government Initiatives
- 11.8.5 Regulations
- 11.8.6 Regulatory Bodies
- 11.8.7 Major Associations
- 11.8.8 Taxes Levied
- 11.8.9 Corporate Tax Structure
- 11.8.10 Investments
- 11.8.11 Major Companies
11.9 China GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.10 China GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.11 China GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.12 India Market
11.13 India GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.14 India GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.15 India GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.16 Japan Market
11.17 Summary
11.18 Market Overview
- 11.18.1 Country Information
- 11.18.2 Market Information
- 11.18.3 Background Information
- 11.18.4 Government Initiatives
- 11.18.5 Regulations
- 11.18.6 Regulatory Bodies
- 11.18.7 Major Associations
- 11.18.8 Taxes Levied
- 11.18.9 Corporate Tax Structure
- 11.18.10 Investments
- 11.18.11 Major Companies
11.19 Japan GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.20 Japan GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.21 Japan GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.22 Australia Market
11.23 Australia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.24 Australia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.25 Australia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.26 Indonesia Market
11.27 Indonesia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.28 Indonesia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.29 Indonesia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.30 South Korea Market
11.31 Summary
11.32 Market Overview
- 11.32.1 Country Information
- 11.32.2 Market Information
- 11.32.3 Background Information
- 11.32.4 Government Initiatives
- 11.32.5 Regulations
- 11.32.6 Regulatory Bodies
- 11.32.7 Major Associations
- 11.32.8 Taxes Levied
- 11.32.9 Corporate Tax Structure
- 11.32.10 Investments
- 11.32.11 Major Companies
11.33 South Korea GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.34 South Korea GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
11.35 South Korea GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

12 Western Europe Market

12.1 Summary
12.2 Market Overview
- 12.2.1 Region Information
- 12.2.2 Market Information
- 12.2.3 Background Information
- 12.2.4 Government Initiatives
- 12.2.5 Regulations
- 12.2.6 Regulatory Bodies
- 12.2.7 Major Associations
- 12.2.8 Taxes Levied
- 12.2.9 Corporate tax structure
- 12.2.10 Investments
- 12.2.11 Major Companies
12.3 Western Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.4 Western Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.5 Western Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.6 Western Europe GLP-1 Receptor Agonist Market: Country Analysis
12.7 UK Market
12.8 UK GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.9 UK GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.10 UK GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.11 Germany Market
12.12 Germany GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.13 Germany GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.14 Germany GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.15 France Market
12.16 France GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.17 France GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.18 France GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.19 Italy Market
12.20 Italy GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.21 Italy GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.22 Italy GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.23 Spain Market
12.24 Spain GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.25 Spain GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
12.26 Spain GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

13 Eastern Europe Market

13.1 Summary
13.2 Market Overview
- 13.2.1 Region Information
- 13.2.2 Market Information
- 13.2.3 Background Information
- 13.2.4 Government Initiatives
- 13.2.5 Regulations
- 13.2.6 Regulatory Bodies
- 13.2.7 Major Associations
- 13.2.8 Taxes Levied
- 13.2.9 Corporate Tax Structure
- 13.2.10 Investments
- 13.2.11 Major companies
13.3 Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
13.4 Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
13.5 Eastern Europe GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
13.6 Eastern Europe GLP-1 Receptor Agonist Market: Country Analysis
13.7 Russia Market
13.8 Russia GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
13.9 Russia GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
13.10 Russia GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

14 North America Market

14.1 Summary
14.2 Market Overview
- 14.2.1 Region Information
- 14.2.2 Market Information
- 14.2.3 Background Information
- 14.2.4 Government Initiatives
- 14.2.5 Regulations
- 14.2.6 Regulatory Bodies
- 14.2.7 Major Associations
- 14.2.8 Taxes Levied
- 14.2.9 Corporate Tax Structure
- 14.2.10 Investments
- 14.2.11 Major Companies
14.3 North America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14.4 North America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14.5 North America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14.6 North America GLP-1 Receptor Agonist Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
- 14.9.1 Country Information
- 14.9.2 Market Information
- 14.9.3 Background Information
- 14.9.4 Government Initiatives
- 14.9.5 Regulations
- 14.9.6 Regulatory Bodies
- 14.9.7 Major Associations
- 14.9.8 Taxes Levied
- 14.9.9 Corporate Tax Structure
- 14.9.10 Investments
- 14.9.11 Major Companies
14.10 USA GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14.11 USA GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14.12 USA GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
- 14.15.1 Country Information
- 14.15.2 Market Information
- 14.15.3 Background Information
- 14.15.4 Government Initiatives
- 14.15.5 Regulations
- 14.15.6 Regulatory Bodies
- 14.15.7 Major Associations
- 14.15.8 Taxes Levied
- 14.15.9 Corporate Tax Structure
- 14.15.10 Investments
- 14.15.11 Major Companies
14.16 Canada GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14.17 Canada GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
14.18 Canada GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

15 South America Market

15.1 Summary
15.2 Market Overview
- 15.2.1 Region Information
- 15.2.2 Market Information
- 15.2.3 Background Information
- 15.2.4 Government Initiatives
- 15.2.5 Regulations
- 15.2.6 Regulatory Bodies
- 15.2.7 Major Associations
- 15.2.8 Taxes Levied
- 15.2.9 Corporate Tax Structure
- 15.2.10 Investments
- 15.2.11 Major Companies
15.3 South America GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
15.4 South America GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
15.5 South America GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
15.6 South America GLP-1 Receptor Agonist Market: Country Analysis
15.7 Brazil Market
15.8 Brazil GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
15.9 Brazil GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
15.10 Brazil GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

16 Middle East Market

16.1 Summary
16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate Tax Structure
- 16.2.10 Investments
- 16.2.11 Major Companies
16.3 Middle East GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
16.4 Middle East GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
16.5 Middle East GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

17 Africa Market

17.1 Summary
17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Associations
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
- 17.2.10 Investments
- 17.2.11 Major Companies
17.3 Africa GLP-1 Receptor Agonist Market, Segmentation By Drug Class, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
17.4 Africa GLP-1 Receptor Agonist Market, Segmentation By Route Of Administration, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)
17.5 Africa GLP-1 Receptor Agonist Market, Segmentation By End Users, Historic And Forecast, 2020 - 2025, 2030F, 2035F, Value ($ Million)

18 Competitive Landscape And Company Profiles

18.1 Company Profiles
18.2 Novo Nordisk AS
- 18.2.1 Company Overview
- 18.2.2 Products And Services
- 18.2.3 Financial Overview
18.3 Eli Lilly Company
- 18.3.1 Company Overview
- 18.3.2 Products And Services
- 18.3.3 Business Strategy
- 18.3.4 Financial Overview
18.4 AstraZeneca Inc.
- 18.4.1 Company Overview
- 18.4.2 Products And Services
- 18.4.3 Financial Overview
18.5 Sanofi SA
- 18.5.1 Company Overview
- 18.5.2 Products And Services
- 18.5.3 Financial Overview
18.6 Glenmark Pharmaceuticals Limited
- 18.6.1 Company Overview
- 18.6.2 Products And Services
- 18.6.3 Financial Overview

19 Other Major And Innovative Companies

19.1 Teva Pharmaceutical Industries Ltd.
- 19.1.1 Company Overview
- 19.1.2 Products And Services
19.2 Amneal Pharmaceuticals
- 19.2.1 Company Overview
- 19.2.2 Products And Services
19.3 Innovent Biologics Inc.
- 19.3.1 Company Overview
- 19.3.2 Products And Services
19.4 Boehringer Ingelheim International GmbH
- 19.4.1 Company Overview
- 19.4.2 Products And Services
19.5 Hanmi Pharm Co. Ltd.
- 19.5.1 Company Overview
- 19.5.2 Products And Services
19.6 Amgen Inc.
- 19.6.1 Company Overview
- 19.6.2 Products And Services
19.7 Sun Pharmaceutical Industries Ltd.
- 19.7.1 Company Overview
- 19.7.2 Products And Services
19.8 Jiangsu Hengrui Medicine Co.
- 19.8.1 Company Overview
- 19.8.2 Products And Services
19.9 Zealand Pharma A/S
- 19.9.1 Company Overview
- 19.9.2 Products And Services
19.10 Dong-A ST Co. Ltd.
- 19.10.1 Company Overview
- 19.10.2 Products And Services
19.11 Novartis AG
- 19.11.1 Company Overview
- 19.11.2 Products And Services
19.12 Hansoh Pharma
- 19.12.1 Company Overview
- 19.12.2 Products And Services
19.13 Structure Therapeutics Inc.
- 19.13.1 Company Overview
- 19.13.2 Products And Services
19.14 Viking Therapeutics
- 19.14.1 Company Overview
- 19.14.2 Products And Services
19.15 Altimmune
- 19.15.1 Company Overview
- 19.15.2 Products And Services

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

22.1 Pfizer Acquired Metsera
22.2 Roche Acquired Carmot

23 Recent Developments In GLP-1 Receptor Agonist

23.1 Advancement Of Small-Molecule Oral GLP-1 Therapies To Improve Accessibility And Ease Of Use

24 Opportunities And Strategies

24.1 Global GLP-1 Receptor Agonist Market In 2030 - Countries Offering Most New Opportunities
24.2 Global GLP-1 Receptor Agonist Market In 2030 - Segments Offering Most New Opportunities
24.3 Global GLP-1 Receptor Agonist Market In 2030 - Growth Strategies
- 24.3.1 Market Trend Based Strategies
- 24.3.2 Competitor Strategies

25 GLP-1 Receptor Agonist Market, Conclusions And Recommendations

25.1 Conclusions
25.2 Recommendations
- 25.2.1 Product
- 25.2.2 Place
- 25.2.3 Price
- 25.2.4 Promotion
- 25.2.5 People

26 Appendix

26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 The Business Research Company
26.6 Copyright and Disclaimer